[Junshi Biological: The first patient was administered in the Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma] On October 23, Junshi Biological (688180.SH) announced that the company’s independently developed recombinant human A randomized, open-label, multi-center Phase III clinical study of the anti-CD20 and CD3 bispecific antibody JS203 combined with chemotherapy versus rituximab combined with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma has completed the administration of the first patient. This study is the first registered clinical study of JS203 and plans to enroll 282 subjects. The primary endpoint is overall survival. Previous phase I clinical data showed that JS203 showed potential anti-tumor efficacy in patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, and the overall safety was controllable.